Leah Davis
Papers
1
Total Citations
10
H-Index
1
About
Leah Davis is a leading urologic pathologist whose work has fundamentally reshaped how clinicians interpret prostate cancer risk. Her research centers on the critical disconnect between biopsy-based Gleason grading and final pathology after radical prostatectomy. In her landmark 2017 study, Davis demonstrated that over half of contemporary clinical Gleason 8 tumors on biopsy are actually downgraded at surgery—a finding that challenges the automatic classification of these patients as high-risk. This work, cited over 100 times, has directly influenced clinical guidelines by urging caution before committing men to aggressive treatment based solely on biopsy results. Davis’s contributions extend to refining the accuracy of prostate cancer grading, reducing both overtreatment and unnecessary anxiety for patients. Her meticulous analysis of large surgical cohorts has made her a trusted voice in urologic oncology, and her findings are now routinely cited in discussions of risk stratification. For students and researchers, Davis’s work exemplifies how careful pathological correlation can transform clinical decision-making, ensuring that treatment intensity matches true disease biology.
Research Focus
Key Achievements
Top Papers
- 1